Who are Bi-PegLyte's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): picosalax plus bisacodyl, SP+MS, Day Before-Only Dosing, Bisacodyl plus PEG-CS.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bi-peglyte.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bi-PegLyte — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bi-PegLyte (Bi-PegLyte) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bowel preparation agent / Laxative combination. Area: Gastroenterology.

marketed Bowel preparation agent / Laxative combination Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Bi-PegLyte (Bi-PegLyte) — University of Manitoba. Bi-PegLyte is a bowel preparation agent that combines bisacodyl and polyethylene glycol to cleanse the colon by osmotic laxation and stimulant action.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Bi-PegLyte TARGET	Bi-PegLyte	University of Manitoba	marketed	Bowel preparation agent / Laxative combination
picosalax plus bisacodyl	picosalax plus bisacodyl	Queen's University	marketed	Bowel preparation agent / Laxative combination
SP+MS, Day Before-Only Dosing	SP+MS, Day Before-Only Dosing	Norgine	phase 3	Bowel preparation agent / Laxative combination
Bisacodyl plus PEG-CS	Bisacodyl plus PEG-CS	European Institute of Oncology	phase 3	Bowel preparation agent / Laxative combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bowel preparation agent / Laxative combination class)

European Institute of Oncology · 1 drug in this class
Norgine · 1 drug in this class
Queen's University · 1 drug in this class
University of Manitoba · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bi-PegLyte — Competitive Intelligence Brief. https://druglandscape.com/ci/bi-peglyte. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing